JP5485153B2 - 電界による寄生生物治療 - Google Patents
電界による寄生生物治療 Download PDFInfo
- Publication number
- JP5485153B2 JP5485153B2 JP2010520642A JP2010520642A JP5485153B2 JP 5485153 B2 JP5485153 B2 JP 5485153B2 JP 2010520642 A JP2010520642 A JP 2010520642A JP 2010520642 A JP2010520642 A JP 2010520642A JP 5485153 B2 JP5485153 B2 JP 5485153B2
- Authority
- JP
- Japan
- Prior art keywords
- electric field
- electrode
- electrodes
- cells
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000005684 electric field Effects 0.000 title claims description 333
- 238000011282 treatment Methods 0.000 title claims description 61
- 244000045947 parasite Species 0.000 title claims description 33
- 239000004020 conductor Substances 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 51
- 230000006378 damage Effects 0.000 claims description 33
- 230000007246 mechanism Effects 0.000 claims description 24
- 230000012010 growth Effects 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 241000243791 Angiostrongylus Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 214
- 206010028980 Neoplasm Diseases 0.000 description 81
- 210000001519 tissue Anatomy 0.000 description 72
- 230000000694 effects Effects 0.000 description 34
- 239000000499 gel Substances 0.000 description 33
- 239000000463 material Substances 0.000 description 32
- 239000012212 insulator Substances 0.000 description 30
- 239000012528 membrane Substances 0.000 description 30
- 230000008569 process Effects 0.000 description 24
- 210000000056 organ Anatomy 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 19
- 239000000523 sample Substances 0.000 description 18
- 238000009826 distribution Methods 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 201000001441 melanoma Diseases 0.000 description 15
- 230000015556 catabolic process Effects 0.000 description 14
- 230000032823 cell division Effects 0.000 description 14
- 210000000170 cell membrane Anatomy 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 150000002500 ions Chemical class 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 208000032612 Glial tumor Diseases 0.000 description 12
- 206010018338 Glioma Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- 210000003463 organelle Anatomy 0.000 description 11
- 210000000481 breast Anatomy 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 239000000853 adhesive Substances 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 9
- 239000003990 capacitor Substances 0.000 description 9
- 210000003722 extracellular fluid Anatomy 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000012404 In vitro experiment Methods 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 238000005868 electrolysis reaction Methods 0.000 description 4
- 238000007667 floating Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000011810 insulating material Substances 0.000 description 4
- 238000007917 intracranial administration Methods 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 210000004718 centriole Anatomy 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000021953 cytokinesis Effects 0.000 description 3
- 239000007933 dermal patch Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 210000002977 intracellular fluid Anatomy 0.000 description 3
- 210000005061 intracellular organelle Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000013021 overheating Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 108091060290 Chromatid Proteins 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000004756 chromatid Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 238000010291 electrical method Methods 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- GQYHUHYESMUTHG-UHFFFAOYSA-N lithium niobate Chemical compound [Li+].[O-][Nb](=O)=O GQYHUHYESMUTHG-UHFFFAOYSA-N 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 235000012771 pancakes Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920006112 polar polymer Polymers 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000006444 vascular growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WSMQKESQZFQMFW-UHFFFAOYSA-N 5-methyl-pyrazole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NN1 WSMQKESQZFQMFW-UHFFFAOYSA-N 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 229910004247 CaCu Inorganic materials 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000222716 Crithidia Species 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 229910013641 LiNbO 3 Inorganic materials 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- JRPBQTZRNDNNOP-UHFFFAOYSA-N barium titanate Chemical compound [Ba+2].[Ba+2].[O-][Ti]([O-])([O-])[O-] JRPBQTZRNDNNOP-UHFFFAOYSA-N 0.000 description 1
- 229910002113 barium titanate Inorganic materials 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000010888 cage effect Methods 0.000 description 1
- 230000003047 cage effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000011231 conductive filler Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000000445 cytocidal effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 238000004720 dielectrophoresis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- NKZSPGSOXYXWQA-UHFFFAOYSA-N dioxido(oxo)titanium;lead(2+) Chemical compound [Pb+2].[O-][Ti]([O-])=O NKZSPGSOXYXWQA-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012777 electrically insulating material Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- ZBSCCQXBYNSKPV-UHFFFAOYSA-N oxolead;oxomagnesium;2,4,5-trioxa-1$l^{5},3$l^{5}-diniobabicyclo[1.1.1]pentane 1,3-dioxide Chemical compound [Mg]=O.[Pb]=O.[Pb]=O.[Pb]=O.O1[Nb]2(=O)O[Nb]1(=O)O2 ZBSCCQXBYNSKPV-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000008759 sweat gland cancer Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Electrotherapy Devices (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Radiation-Therapy Devices (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95571907P | 2007-08-14 | 2007-08-14 | |
| US60/955,719 | 2007-08-14 | ||
| PCT/IB2008/002134 WO2009022225A1 (en) | 2007-08-14 | 2008-08-13 | Treating parasites with electric fields |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010536406A JP2010536406A (ja) | 2010-12-02 |
| JP2010536406A5 JP2010536406A5 (cg-RX-API-DMAC7.html) | 2011-12-22 |
| JP5485153B2 true JP5485153B2 (ja) | 2014-05-07 |
Family
ID=40219471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520642A Active JP5485153B2 (ja) | 2007-08-14 | 2008-08-13 | 電界による寄生生物治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7890183B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2183024B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5485153B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101820947A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2696352C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2183024T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2739384T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2183024T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009022225A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018097185A1 (ja) | 2016-11-24 | 2018-05-31 | 公立大学法人横浜市立大学 | がん治療装置 |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416466A (zh) | 2000-02-17 | 2003-05-07 | 约朗姆·帕尔蒂 | 破坏正在分裂的细胞的方法和装置 |
| US7890183B2 (en) | 2000-02-17 | 2011-02-15 | Novocure Ltd. | Treating parasites with electric fields |
| US8175698B2 (en) * | 2000-02-17 | 2012-05-08 | Novocure Ltd. | Treating bacteria with electric fields |
| US8447395B2 (en) * | 2000-02-17 | 2013-05-21 | Novocure Ltd | Treating bacteria with electric fields |
| DE10260149A1 (de) | 2002-12-20 | 2004-07-01 | BSH Bosch und Siemens Hausgeräte GmbH | Vorrichtung zur Bestimmung des Leitwertes von Wäsche, Wäschetrockner und Verfahren zur Verhinderung von Schichtbildung auf Elektroden |
| JP4750784B2 (ja) | 2004-04-23 | 2011-08-17 | ノヴォキュアー・リミテッド | 異なる周波数の電界による腫瘍等の治療 |
| US7715921B2 (en) * | 2004-12-07 | 2010-05-11 | Standen Ltd. | Electrodes for applying an electric field in-vivo over an extended period of time |
| CA2624624C (en) * | 2005-10-03 | 2016-07-19 | Novocure Limited | Optimizing characteristics of an electric field to increase the field's effect on proliferating cells |
| US8019414B2 (en) * | 2006-04-05 | 2011-09-13 | Novocure Ltd. | Treating cancer using electromagnetic fields in combination with other treatment regimens |
| WO2008063338A2 (en) * | 2006-10-18 | 2008-05-29 | Buckeye Pharmaceuticals, Llc | Chemical compound delivery device and method |
| PT2167194T (pt) * | 2007-03-06 | 2017-06-15 | Novocure Ltd | Tratamento do cancro utilizando campos electromagnéticos em combinação com terapia fotodinámica |
| US8992593B2 (en) * | 2007-12-26 | 2015-03-31 | Cook Medical Technologies Llc | Apparatus and methods for deployment of a modular stent-graft system |
| US8684901B1 (en) | 2010-11-22 | 2014-04-01 | Jacob Zabara | Electromagnetic radiation treatment for cancer and pathological genetic regulations |
| US9233257B1 (en) | 2010-11-22 | 2016-01-12 | Jacob Zabara | Electromagnetic radiation treatment |
| AU2012364909B2 (en) | 2011-02-15 | 2016-11-24 | Hemosonics, Llc | Characterization of blood hemostasis and oxygen transport parameters |
| EP2522389A3 (en) * | 2011-05-13 | 2014-08-27 | Sergio Lara Pereira Monteiro | Animal and plant cell electric stimulator with randomized spatial distribution of electrodes for both current injection and for electric field shaping |
| US9486625B2 (en) | 2011-08-08 | 2016-11-08 | Medamp Electronics, Llc | Method for treating benign prostate hyperplasia |
| US8706258B2 (en) | 2011-08-08 | 2014-04-22 | Medamp Electronics, Llc | Method and apparatus for treating cancer |
| DE102012015482A1 (de) * | 2012-08-07 | 2014-02-13 | Cinogy Gmbh | Elektrodenanordnung für ein behindertes Plasma |
| DE102012025052A1 (de) * | 2012-12-20 | 2014-06-26 | Fresenius Medical Care Deutschland Gmbh | Hämodiafiltrationsverfahren |
| US10779875B2 (en) | 2013-05-06 | 2020-09-22 | Novocure Gmbh | Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment |
| US9655669B2 (en) | 2013-05-06 | 2017-05-23 | Novocure Limited | Optimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment |
| US20190117963A1 (en) * | 2014-07-25 | 2019-04-25 | Loyalty Based Innovations, LLC | Apparatus and method for treating multiple tumors in patients with metastatic disease by electric fields |
| US9726647B2 (en) | 2015-03-17 | 2017-08-08 | Hemosonics, Llc | Determining mechanical properties via ultrasound-induced resonance |
| US10188851B2 (en) | 2015-10-28 | 2019-01-29 | Novocure Limited | TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements |
| US10821283B2 (en) | 2016-04-04 | 2020-11-03 | Novocure Gmbh | Reducing motility of cancer cells using tumor treating fields (TTFields) |
| EP4454697A3 (en) | 2016-06-30 | 2024-12-25 | Novocure GmbH | Arrays for longitudinal delivery of ttfields to a body |
| EP3571503A1 (en) | 2017-01-19 | 2019-11-27 | Moshe Giladi | System for viewing cell cultures under a microscope whilst applying ttfields |
| US11364390B2 (en) * | 2017-02-07 | 2022-06-21 | Santi Tofani | Apparatus for treating pathological cells |
| US11338135B2 (en) | 2017-10-23 | 2022-05-24 | Cardiac Pacemakers, Inc. | Medical devices for cancer therapy with electric field shaping elements |
| US12403306B2 (en) | 2017-10-23 | 2025-09-02 | Cardiac Pacemakers, Inc. | Electric field shaping leads for treatment of cancer |
| US10953209B2 (en) | 2018-03-28 | 2021-03-23 | Board Of Regents Of The University Of Texas System | Treating tumors using TTFields combined with a PARP inhibitor |
| CN112566665A (zh) | 2018-04-09 | 2021-03-26 | 莫舍·吉拉迪 | 用TTFields和Aurora激酶抑制剂治疗肿瘤 |
| JP7225373B2 (ja) | 2018-04-10 | 2023-02-20 | ゼーヴ・ボンゾン | 異なる繰返し時間を有する２つのＭＲＩ画像から導出される低周波数（＜１ＭＨｚ）交流導電率推定 |
| CN114082099A (zh) | 2018-07-03 | 2022-02-25 | 埃德温·阊 | 使用交变电场提高细胞膜通透性 |
| US11583675B2 (en) | 2018-07-10 | 2023-02-21 | Novocure Gmbh | Inhibiting viral infection using alternating electric fields |
| US11179322B2 (en) | 2018-07-10 | 2021-11-23 | Novocure Gmbh | Methods and compositions for treating tumors with TTFields and sorafenib |
| US11911612B2 (en) | 2018-07-18 | 2024-02-27 | Novocure Gmbh | Using power loss density and related measures to quantify the dose of tumor treating fields (TTFields) |
| CA3242209A1 (en) | 2018-08-23 | 2020-02-27 | Novocure Gmbh | Using alternating electric fields to increase permeability of the blood brain barrier |
| US11160977B2 (en) | 2018-09-04 | 2021-11-02 | Novocure Gmbh | Delivering tumor treating fields (TTFields) to the infratentorial brain |
| US11986647B2 (en) | 2018-09-07 | 2024-05-21 | Novocure Gmbh | Treating autoinflammatory and mitochondrial diseases using an alternating electric field |
| US11020585B2 (en) | 2018-09-07 | 2021-06-01 | Novocure Gmbh | Treating autoimmune diseases using an alternating electric field to reduce the proliferation of t-cells |
| CN118925056A (zh) | 2018-10-15 | 2024-11-12 | 诺沃库勒有限责任公司 | 生成遍及大脑具有高均匀性的肿瘤治疗场（ttfields） |
| CN112955208B (zh) * | 2018-10-25 | 2024-11-22 | 诺沃库勒有限责任公司 | 向受试者的脊柱解剖结构递送交变电场(例如，ttfields)的方法 |
| US12186575B2 (en) | 2018-11-13 | 2025-01-07 | The Methodist Hospital | Method and apparatus for oncomagnetic treatment |
| IL280843B2 (en) | 2018-11-19 | 2025-10-01 | Novocure Gmbh | Arrays for providing fields treat growth with selectively addressable sub-elements |
| CN118079235A (zh) | 2018-11-29 | 2024-05-28 | 诺沃库勒有限责任公司 | 用于递送TTField（肿瘤治疗场）的增强灵活性换能器阵列 |
| JP7246486B2 (ja) | 2019-01-08 | 2023-03-27 | ノボキュア ゲーエムベーハー | 腫瘍治療電場（ｔｔｆｉｅｌｄｓ）を使用した治療を計画するための異なるタイプの組織への画像のセグメンテーションの品質評価 |
| US11027143B2 (en) | 2020-02-06 | 2021-06-08 | Vivek K. Sharma | System and methods for treating cancer cells with alternating polarity magnetic fields |
| US11344740B2 (en) | 2019-02-07 | 2022-05-31 | Asha Medical, Inc. | System and methods for treating cancer cells with alternating polarity magnetic fields |
| JP2022519782A (ja) | 2019-02-07 | 2022-03-24 | ヴィヴェーク・ケー・シャルマ | 交番極性磁場によってがん細胞を治療するシステム、および方法 |
| EP3974022B1 (en) | 2019-02-26 | 2024-04-17 | Novocure GmbH | Determining a frequency for ttfields treatment based on a physical parameter of targeted cancer cells |
| US11471676B2 (en) | 2019-02-27 | 2022-10-18 | Novocure Gmbh | Delivering tumor treating fields (TTFields) using implantable transducer arrays |
| FR3093645B1 (fr) * | 2019-03-15 | 2021-04-02 | Univ Montpellier | Puce microfluidique pour attirer et détruire un élément biologique spécifique |
| DK3946322T3 (da) | 2019-03-29 | 2023-11-27 | Novocure Gmbh | Fremgangsmåder til genoprettelse af sensitivitet over for ttfields i ttfields-resistente kræftceller med ptger3-inhibitorer |
| HUE061231T2 (hu) | 2019-04-17 | 2023-05-28 | Novocure Gmbh | Adatok feltöltése egy szigetelt rendszerbõl a szigetelés veszélyeztetése nélkül |
| WO2020219337A1 (en) | 2019-04-22 | 2020-10-29 | Boston Scientific Scimed, Inc. | Systems for administering electrical stimulation to treat cancer |
| EP3958954B1 (en) | 2019-04-22 | 2024-04-24 | Boston Scientific Scimed Inc. | Electrical stimulation devices for cancer treatment |
| CN113766948B (zh) | 2019-04-22 | 2025-02-07 | 波士顿科学国际有限公司 | 对癌症的电与化学组合治疗 |
| CN113747936B (zh) | 2019-04-23 | 2024-06-18 | 波士顿科学国际有限公司 | 用于电刺激来治疗癌症的电极 |
| CN113766950A (zh) | 2019-04-23 | 2021-12-07 | 波士顿科学国际有限公司 | 带有热治疗或热监测的电刺激 |
| US11607542B2 (en) | 2019-04-23 | 2023-03-21 | Boston Scientific Scimed, Inc. | Electrical stimulation for cancer treatment with internal and external electrodes |
| US11654279B2 (en) | 2019-07-31 | 2023-05-23 | Novocure Gmbh | Applying tumor treating fields (TTFields) via electrodes embedded into skull implants |
| US12343336B2 (en) | 2019-08-05 | 2025-07-01 | Novocure Gmbh | Increasing cancer cells' sensitivity to tumor treating fields (TTFields) by inhibiting IL11 activity |
| JP2022545794A (ja) | 2019-08-30 | 2022-10-31 | ノボキュア ゲーエムベーハー | 頸部への腫瘍治療電界（ＴＴＦｉｅｌｄｓ）の印加 |
| WO2021116754A2 (en) * | 2019-12-11 | 2021-06-17 | Novocure Gmbh | Compositions and methods of altering the electric impedance to an alternating electric field |
| CA3163316A1 (en) | 2019-12-31 | 2021-07-08 | Novocure Gmbh | Arrays for delivering tumor treating fields (ttfields) with individually accessible electrode elements and temperature sensors |
| EP4054705B1 (en) | 2019-12-31 | 2024-10-23 | Novocure GmbH | High voltage, high efficiency sine wave generator that prevents spikes during amplitude adjustments and switching of channels |
| US12121739B2 (en) | 2019-12-31 | 2024-10-22 | Novocure Gmbh | Methods, systems, and apparatuses for managing temperatures induced by alternating fields |
| US11883655B2 (en) | 2020-02-24 | 2024-01-30 | Boston Scientific Scimed, Inc. | Systems and methods for treatment of pancreatic cancer |
| US20210299440A1 (en) | 2020-03-30 | 2021-09-30 | Novocure Gmbh | Intravenous / Intra-Spinal / Intra-Cavity / Intraventricular Delivery of TTFields (Tumor Treating Fields) for Treating Cancer and Metastases |
| EP4138988A1 (en) | 2020-04-24 | 2023-03-01 | Novocure Gmbh | Using alternating electric fields to increase permeability of the blood brain barrier |
| TWI889816B (zh) | 2020-05-06 | 2025-07-11 | 瑞士商諾沃庫勒有限責任公司 | 用於產生腫瘤治療電場之導電襯墊以及生產和使用其之方法 |
| EP4168108A4 (en) | 2020-06-19 | 2024-07-17 | The Methodist Hospital dba Houston Methodist Hospital | METHOD AND APPARATUS FOR ONCOMAGNETIC TREATMENT |
| US11818943B2 (en) | 2020-06-25 | 2023-11-14 | Novocure Gmbh | Fabricating organic light emitting diodes (OLEDs) using tubulin |
| KR102490645B1 (ko) * | 2020-07-16 | 2023-01-25 | 고려대학교 산학협력단 | 흡수에너지 기반 전기장 암치료 계획 시스템 및 방법 |
| US12114991B2 (en) | 2020-09-25 | 2024-10-15 | Novocure Gmbh | Varying the metallization area on individual electrode elements in a tumor treating fields (TTFields) system to maximize current without overheating |
| DE102021102884A1 (de) * | 2021-02-08 | 2022-08-11 | Elea Vertriebs- Und Vermarktungsgesellschaft Mbh | Verfahren zum Paralysieren von Parasiten in Nahrung, insbesondere in einem Lebens- oder Futtermittel und damit hergestelltes Lebensmittel mit paralysierten Parasiten |
| EP4240470A1 (en) | 2021-02-17 | 2023-09-13 | Novocure Gmbh | Arrays for delivering tumor treating fields (ttfields) with sets of electrode elements having individually adjustable active areas |
| US12440680B2 (en) | 2021-03-12 | 2025-10-14 | Novocure Gmbh | Methods of treating disease by skewing macrophage phenotype with alternating electric fields |
| US20220305277A1 (en) * | 2021-03-23 | 2022-09-29 | Novocure Gmbh | Methods and apparatuses for detecting and responding to changes in a subject |
| US12201831B2 (en) | 2021-03-31 | 2025-01-21 | Novocure Gmbh | Impedance tomography using electrodes of a tumor treating fields (TTFields) system |
| US12496443B2 (en) | 2021-06-22 | 2025-12-16 | Lifebridge Innovations, Pbc | Apparatus and method for improving electric field therapy to reduce solid tumors |
| US20230009366A1 (en) * | 2021-06-30 | 2023-01-12 | Novocure Gmbh | Using Alternating Electric Fields at Different Frequencies to Increase Permeability of the Blood Brain Barrier and also to Provide Other Benefits |
| CN113663215B (zh) * | 2021-10-22 | 2022-01-21 | 杭州维纳安可医疗科技有限责任公司 | 电场发生装置及其控制方法、计算机可读存储介质 |
| US20230173265A1 (en) * | 2021-12-10 | 2023-06-08 | Novocure Gmbh | Garment providing a biasing force on a transducer array |
| EP4456971A1 (en) | 2021-12-30 | 2024-11-06 | Novocure GmbH | Selecting values of parameters for treatment using tumor treating fields (ttfields) |
| MX2024010256A (es) | 2022-03-30 | 2024-08-28 | Novocure Gmbh | Reducción de la electrosensación durante el tratamiento de un sujeto mediante campos eléctricos alternos mediante el emparejamiento de matrices de transductores. |
| JP2025511071A (ja) | 2022-03-30 | 2025-04-15 | ノボキュア ゲーエムベーハー | インターリーブ冷却期間による腫瘍治療場のピーク強度強化 |
| JP2025512896A (ja) | 2022-04-01 | 2025-04-22 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 個別化超分割定位適応放射線療法と併用した腫瘍治療電場を印加するための方法および装置 |
| WO2024141916A1 (en) * | 2022-12-28 | 2024-07-04 | Novocure Gmbh | Wearable garment with integrated tumor treating fields voltage generator |
| US12268863B2 (en) | 2023-02-06 | 2025-04-08 | Novocure Gmbh | Shiftable transducer array with anisotropic material layer |
| CN116020054B (zh) * | 2023-02-24 | 2023-12-08 | 北京微脊医疗科技有限公司 | 植入式电场治疗装置 |
| US12465759B2 (en) | 2023-03-14 | 2025-11-11 | Boris Kriman | Electrostatic therapeutic device |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR446660A (fr) * | 1911-09-02 | 1912-12-12 | Gottlieb Schuettel | Dispositif pour métiers continus à anneaux pour monter les curseurs sur les anneaux |
| BE794566A (fr) | 1972-01-28 | 1973-07-26 | Esb Inc | Regenerateur et stimulateur bioelectrochimique et procedes d'application in vivo d'energie electrique a des cellules et des tissus. |
| US3991770A (en) * | 1974-01-24 | 1976-11-16 | Leveen Harry H | Method for treating benign and malignant tumors utilizing radio frequency, electromagnetic radiation |
| US4016886A (en) * | 1974-11-26 | 1977-04-12 | The United States Of America As Represented By The United States Energy Research And Development Administration | Method for localizing heating in tumor tissue |
| US4121592A (en) * | 1975-08-04 | 1978-10-24 | Critical Systems, Inc. | Apparatus for heating tissue |
| DE2907013A1 (de) | 1978-02-24 | 1979-08-30 | American Med Syst | Verfahren und vorrichtung zum beguenstigen der heilung von verletzten knochenknorpeln und geweben im gesichtsbereich |
| DE2813068A1 (de) * | 1978-03-25 | 1979-10-04 | Philips Patentverwaltung | Verfahren und vorrichtung zur ermittlung von inneren koerperstrukturen |
| GB2043453A (en) | 1979-02-22 | 1980-10-08 | Electrochem Tech Corp | Improvements in or relating to an electrode |
| US4472506A (en) * | 1981-01-13 | 1984-09-18 | Liburdy Robert P | Method for determining cell membrane dielectric breakdown |
| US4467809A (en) * | 1982-09-17 | 1984-08-28 | Biolectron, Inc. | Method for non-invasive electrical stimulation of epiphyseal plate growth |
| US4622952A (en) * | 1983-01-13 | 1986-11-18 | Gordon Robert T | Cancer treatment method |
| CA1244889A (en) * | 1983-01-24 | 1988-11-15 | Kureha Chemical Ind Co Ltd | HYPERTHERMIA DEVICE |
| DE3323415C2 (de) * | 1983-06-29 | 1985-04-25 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verwendung eines Verfahrens und einer Vorrichtung zur Bestimmung von Zellinhaltstoffe sezernierenden Zellen |
| SE455920B (sv) * | 1986-01-29 | 1988-08-22 | Hans Wiksell | Anordning for hypertermibehandling av tumorer |
| US4923814A (en) * | 1986-05-09 | 1990-05-08 | Electropore, Inc. | High speed, high power apparatus for vesicle prealignment, poration, loading and fusion in uniform electric fields and method therefor |
| CN86103803B (zh) * | 1986-06-05 | 1987-11-18 | 北京信息工程学院 | 静电场治疗装置 |
| US4822470A (en) * | 1987-10-09 | 1989-04-18 | Baylor College Of Medicine | Method of and apparatus for cell poration and cell fusion using radiofrequency electrical pulses |
| US4936303A (en) * | 1987-11-20 | 1990-06-26 | Ultrathermics | Ultrasonic heating apparatus and method |
| JPH0629196B2 (ja) * | 1987-12-01 | 1994-04-20 | 甲子郎 梅村 | 超音波による腫瘍治療用生理作用増強剤 |
| US5389069A (en) * | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
| FR2627987B3 (fr) | 1988-03-04 | 1990-02-02 | Indiba Sa | Appareil electronique pour la therapie medicale et cosmetique |
| US5158071A (en) * | 1988-07-01 | 1992-10-27 | Hitachi, Ltd. | Ultrasonic apparatus for therapeutical use |
| GB8904998D0 (en) * | 1989-03-04 | 1989-04-19 | Matthews Tony | Anaesthetising apparatus |
| US5099756A (en) * | 1989-06-01 | 1992-03-31 | Harry H. Leveen | Radio frequency thermotherapy |
| US5441746A (en) * | 1989-12-22 | 1995-08-15 | Molecular Bioquest, Inc. | Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production |
| US5236410A (en) * | 1990-08-02 | 1993-08-17 | Ferrotherm International, Inc. | Tumor treatment method |
| WO1992019286A1 (en) * | 1991-05-03 | 1992-11-12 | University Technologies International, Inc. | Biofilm reduction method |
| US5441532A (en) * | 1991-06-26 | 1995-08-15 | Massachusetts Institute Of Technology | Adaptive focusing and nulling hyperthermia annular and monopole phased array applicators |
| US5468223A (en) * | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
| US5386837A (en) * | 1993-02-01 | 1995-02-07 | Mmtc, Inc. | Method for enhancing delivery of chemotherapy employing high-frequency force fields |
| FR2703253B1 (fr) * | 1993-03-30 | 1995-06-23 | Centre Nat Rech Scient | Applicateur d'impulsions electriques pour traitement de tissus biologiques. |
| IL108775A (en) * | 1994-02-25 | 2003-09-17 | Univ Ramot | Method for efficient incorporation of molecules into cells |
| US5704355A (en) * | 1994-07-01 | 1998-01-06 | Bridges; Jack E. | Non-invasive system for breast cancer detection |
| AU6639596A (en) * | 1995-07-28 | 1997-02-26 | James R. Gray | Use of a polarizing field to modify the efficacy of a bioactive agent |
| US5606971A (en) * | 1995-11-13 | 1997-03-04 | Artann Corporation, A Nj Corp. | Method and device for shear wave elasticity imaging |
| US5718246A (en) * | 1996-01-03 | 1998-02-17 | Preferential, Inc. | Preferential induction of electrically mediated cell death from applied pulses |
| US5984882A (en) * | 1996-08-19 | 1999-11-16 | Angiosonics Inc. | Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy |
| US5869326A (en) * | 1996-09-09 | 1999-02-09 | Genetronics, Inc. | Electroporation employing user-configured pulsing scheme |
| US6055453A (en) * | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| AU9472998A (en) * | 1997-09-04 | 1999-03-22 | Science Research Laboratory, Inc. | Cell separation using electric fields |
| US6027488A (en) * | 1998-06-03 | 2000-02-22 | Genetronics, Inc. | Flow-through electroporation system for ex vivo gene therapy |
| US5976092A (en) * | 1998-06-15 | 1999-11-02 | Chinn; Douglas O. | Combination stereotactic surgical guide and ultrasonic probe |
| US6319901B1 (en) * | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
| WO2000053113A1 (en) * | 1999-03-09 | 2000-09-14 | Thermage, Inc. | Apparatus and method for treatment of tissue |
| US6678558B1 (en) * | 1999-03-25 | 2004-01-13 | Genetronics, Inc. | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response |
| US6366808B1 (en) * | 2000-03-13 | 2002-04-02 | Edward A. Schroeppel | Implantable device and method for the electrical treatment of cancer |
| US6853864B2 (en) * | 2000-02-02 | 2005-02-08 | Catholic University Of America, The | Use of electromagnetic fields in cancer and other therapies |
| US7089054B2 (en) * | 2002-10-02 | 2006-08-08 | Standen Ltd. | Apparatus and method for treating a tumor or the like |
| US7136699B2 (en) * | 2002-10-02 | 2006-11-14 | Standen, Ltd. | Apparatus for destroying dividing cells |
| US7890183B2 (en) | 2000-02-17 | 2011-02-15 | Novocure Ltd. | Treating parasites with electric fields |
| US7599746B2 (en) * | 2000-02-17 | 2009-10-06 | Standen Ltd | Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases |
| US7016725B2 (en) * | 2001-11-06 | 2006-03-21 | Standen Ltd. | Method and apparatus for destroying dividing cells |
| US6868289B2 (en) * | 2002-10-02 | 2005-03-15 | Standen Ltd. | Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor |
| US8175698B2 (en) * | 2000-02-17 | 2012-05-08 | Novocure Ltd. | Treating bacteria with electric fields |
| CN1416466A (zh) * | 2000-02-17 | 2003-05-07 | 约朗姆·帕尔蒂 | 破坏正在分裂的细胞的方法和装置 |
| US7146210B2 (en) * | 2000-02-17 | 2006-12-05 | Standen Ltd. | Apparatus and method for optimizing tumor treatment efficiency by electric fields |
| US6546290B1 (en) * | 2000-04-12 | 2003-04-08 | Roamitron Holding S.A. | Method and apparatus for electromedical therapy |
| US6994706B2 (en) * | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
| US8986944B2 (en) * | 2001-10-11 | 2015-03-24 | Aviva Biosciences Corporation | Methods and compositions for separating rare cells from fluid samples |
| JP4750784B2 (ja) * | 2004-04-23 | 2011-08-17 | ノヴォキュアー・リミテッド | 異なる周波数の電界による腫瘍等の治療 |
| DE102004028156A1 (de) * | 2004-06-09 | 2006-01-05 | Kalbe, Jochen, Dr. | Kombination von Radiowellen mit pharmakologisch aktiven Substanzen |
| US7715921B2 (en) * | 2004-12-07 | 2010-05-11 | Standen Ltd. | Electrodes for applying an electric field in-vivo over an extended period of time |
| CA2594231C (en) * | 2004-12-27 | 2016-04-19 | Standen Ltd. | Treating a tumor or the like with electric fields at different orientations |
| DK1899001T3 (en) * | 2005-06-08 | 2017-12-04 | Novocure Ltd | DEVICE FOR CANCER TREATMENT WITH ELECTRIC FIELDS MADE FOR DESIRED LOCATIONS IN A BODY |
| CA2624624C (en) * | 2005-10-03 | 2016-07-19 | Novocure Limited | Optimizing characteristics of an electric field to increase the field's effect on proliferating cells |
| US8019414B2 (en) * | 2006-04-05 | 2011-09-13 | Novocure Ltd. | Treating cancer using electromagnetic fields in combination with other treatment regimens |
| PT2167194T (pt) * | 2007-03-06 | 2017-06-15 | Novocure Ltd | Tratamento do cancro utilizando campos electromagnéticos em combinação com terapia fotodinámica |
| US8715203B2 (en) * | 2007-09-17 | 2014-05-06 | Novocure Limited | Composite electrode |
-
2008
- 2008-08-13 US US12/190,886 patent/US7890183B2/en not_active Expired - Lifetime
- 2008-08-13 CN CN200880111479A patent/CN101820947A/zh active Pending
- 2008-08-13 CA CA2696352A patent/CA2696352C/en active Active
- 2008-08-13 JP JP2010520642A patent/JP5485153B2/ja active Active
- 2008-08-13 WO PCT/IB2008/002134 patent/WO2009022225A1/en not_active Ceased
- 2008-08-13 EP EP08789083.6A patent/EP2183024B1/en active Active
- 2008-08-13 PT PT08789083T patent/PT2183024T/pt unknown
- 2008-08-13 DK DK08789083.6T patent/DK2183024T3/da active
- 2008-08-13 ES ES08789083T patent/ES2739384T3/es active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018097185A1 (ja) | 2016-11-24 | 2018-05-31 | 公立大学法人横浜市立大学 | がん治療装置 |
| US11383094B2 (en) | 2016-11-24 | 2022-07-12 | Public University Corporation Yokohama City University | Cancer treatment apparatus |
| EP4302820A2 (en) | 2016-11-24 | 2024-01-10 | Public University Corporation Yokohama City University | Cancer treatment apparatus |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2696352C (en) | 2017-03-21 |
| EP2183024B1 (en) | 2019-05-15 |
| CN101820947A (zh) | 2010-09-01 |
| PT2183024T (pt) | 2019-08-01 |
| CA2696352A1 (en) | 2009-02-19 |
| WO2009022225A1 (en) | 2009-02-19 |
| US20090043346A1 (en) | 2009-02-12 |
| ES2739384T3 (es) | 2020-01-30 |
| JP2010536406A (ja) | 2010-12-02 |
| DK2183024T3 (da) | 2019-06-24 |
| EP2183024A1 (en) | 2010-05-12 |
| US7890183B2 (en) | 2011-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5485153B2 (ja) | 電界による寄生生物治療 | |
| JP4750784B2 (ja) | 異なる周波数の電界による腫瘍等の治療 | |
| CA2697012C (en) | Treating bacteria with electric fields | |
| JP4350042B2 (ja) | 腫瘍等を治療するための装置ならびに腫瘍の治療のための装置を備えた製品 | |
| CN101124011B (zh) | 利用电场从不同方向治疗肿瘤等 | |
| HK40030557A (en) | Apparatus for treating a tumor by an electric field | |
| HK40013151B (en) | Apparatus for treating a tumor by an electric field | |
| HK40013151A (en) | Apparatus for treating a tumor by an electric field | |
| HK1153964B (en) | Apparatus for treating a tumor by an electric field | |
| HK1153963B (en) | Apparatus for treating a tumor by an electric field | |
| HK1153964A (en) | Apparatus for treating a tumor by an electric field |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111011 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130425 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130507 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130527 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130603 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130626 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130729 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140219 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5485153 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |